In the metastatic setting associated with bone loss, dysregulated RANKL expression by the OB lineage and tumor-associated immune cells promotes excessive osteoclastogenesis and matrix degradation (21, 25, 26). The gene discussed is TNFSF11; the disease is neoplasm.